WO2004065545A3 - Diagnosis and prognosis of breast cancer patients - Google Patents

Diagnosis and prognosis of breast cancer patients Download PDF

Info

Publication number
WO2004065545A3
WO2004065545A3 PCT/US2004/001100 US2004001100W WO2004065545A3 WO 2004065545 A3 WO2004065545 A3 WO 2004065545A3 US 2004001100 W US2004001100 W US 2004001100W WO 2004065545 A3 WO2004065545 A3 WO 2004065545A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
relates
prognosis
diagnosis
whose expression
Prior art date
Application number
PCT/US2004/001100
Other languages
French (fr)
Other versions
WO2004065545A2 (en
Inventor
T Veer Laura Johanna Van
Yudong He
Original Assignee
Rosetta Inpharmatics Llc
Netherlands Cancer Inst
T Veer Laura Johanna Van
Yudong He
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Inpharmatics Llc, Netherlands Cancer Inst, T Veer Laura Johanna Van, Yudong He filed Critical Rosetta Inpharmatics Llc
Priority to JP2006500977A priority Critical patent/JP4619350B2/en
Priority to CA002513642A priority patent/CA2513642A1/en
Priority to EP04702566A priority patent/EP1590433A4/en
Publication of WO2004065545A2 publication Critical patent/WO2004065545A2/en
Publication of WO2004065545A3 publication Critical patent/WO2004065545A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also provides methods of classifying and treating patients based on prognosis. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the diagnostic, prognostic and statistical methods disclosed herein.
PCT/US2004/001100 2003-01-15 2004-01-15 Diagnosis and prognosis of breast cancer patients WO2004065545A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006500977A JP4619350B2 (en) 2003-01-15 2004-01-15 Diagnosis and prognosis of breast cancer patients
CA002513642A CA2513642A1 (en) 2003-01-15 2004-01-15 Diagnosis and prognosis of breast cancer patients
EP04702566A EP1590433A4 (en) 2003-01-15 2004-01-15 Diagnosis and prognosis of breast cancer patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/342,887 2003-01-15
US10/342,887 US7171311B2 (en) 2001-06-18 2003-01-15 Methods of assigning treatment to breast cancer patients

Publications (2)

Publication Number Publication Date
WO2004065545A2 WO2004065545A2 (en) 2004-08-05
WO2004065545A3 true WO2004065545A3 (en) 2005-06-02

Family

ID=32770203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001100 WO2004065545A2 (en) 2003-01-15 2004-01-15 Diagnosis and prognosis of breast cancer patients

Country Status (5)

Country Link
US (1) US7171311B2 (en)
EP (1) EP1590433A4 (en)
JP (1) JP4619350B2 (en)
CA (1) CA2513642A1 (en)
WO (1) WO2004065545A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
WO2002072828A1 (en) * 2001-03-14 2002-09-19 Dna Chip Research Inc. Method of predicting cancer
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
AU2002316251A1 (en) 2001-06-18 2003-01-02 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
DE60238143D1 (en) * 2001-09-18 2010-12-09 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
US9222938B2 (en) * 2001-12-04 2015-12-29 Michael Tainsky Neoepitope detection of disease using protein arrays
AU2003212954A1 (en) * 2002-02-08 2003-09-02 Integriderm, Inc. Skin cell biomarkers and methods for identifying biomarkers using nucleic acid microarrays
AU2003205913A1 (en) * 2002-02-20 2003-09-09 Ncc Technology Ventures Pte Limited Materials and methods relating to cancer diagnosis
ATE448297T1 (en) * 2002-03-14 2009-11-15 Nat Inst Of Advanced Ind Scien N-ACETYL GLUCOSAMINE TRANSFERASE, NUCLEIC ACID CODING SUCH, AND USE THEREOF IN THE DIAGNOSES OF CANCER AND/OR A TUMOR
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US20060089493A1 (en) * 2002-04-30 2006-04-27 Biogen Idec Inc. Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
KR20050048615A (en) * 2002-08-19 2005-05-24 제넨테크, 인크. Compositions and methods for the diagnosis and treatment of tumor
US7517648B2 (en) * 2002-08-26 2009-04-14 The Regents Of The University Of Michigan NPHP nucleic acids and proteins
EP1557466B1 (en) * 2002-09-27 2009-09-02 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen protein and utilization thereof
US7217515B2 (en) * 2002-09-30 2007-05-15 Chi Mei Foundation Medical Center HURP gene as a molecular marker for bladder cancer
GB0307428D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US7306910B2 (en) 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
JP4434621B2 (en) * 2003-05-07 2010-03-17 キヤノン株式会社 Medical image forming apparatus and method
JP2007516693A (en) * 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Compositions and methods for the treatment and diagnosis of cancer
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US20050112622A1 (en) 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
DE10344799A1 (en) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
US20050069863A1 (en) * 2003-09-29 2005-03-31 Jorge Moraleda Systems and methods for analyzing gene expression data for clinical diagnostics
KR20060120063A (en) 2003-09-29 2006-11-24 패스워크 인포메틱스 아이엔씨 Systems and methods for detecting biological features
US8321137B2 (en) * 2003-09-29 2012-11-27 Pathwork Diagnostics, Inc. Knowledge-based storage of diagnostic models
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
US20080113344A1 (en) * 2003-10-28 2008-05-15 Ralph Wirtz Methods and Compositions for the Response Prediction of Malignant Neoplasia to Treatment
FR2861744A1 (en) * 2003-11-05 2005-05-06 Biomerieux Sa METHOD FOR THE PROGNOSIS OF BREAST CANCER
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
WO2005078629A2 (en) * 2004-02-10 2005-08-25 Koninklijke Philips Electronics, N.V. Genetic algorithms for optimization of genomics-based medical diagnostic tests
EP1584684A1 (en) * 2004-02-20 2005-10-12 Samsung Electronics Co., Ltd. Breast cancer related protein, gene encoding the same, and method of diagnosing breast cancer using the protein and gene
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
CA2558808A1 (en) * 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
AU2005224614A1 (en) * 2004-03-12 2005-09-29 Exelixis, Inc. PDES as modifiers of the IGFR pathway and methods of use
US20050221339A1 (en) * 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
MXPA06011538A (en) * 2004-04-06 2007-01-26 Univ California Orphan receptor tyrosine kinase as a target in breast cancer.
JP5813908B2 (en) * 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド Gene expression markers to predict response to chemotherapeutic agents
JP2007532142A (en) * 2004-04-23 2007-11-15 エグザジェン ダイアグノスティクス インコーポレイテッド Breast cancer gene expression biomarker
JP2007530075A (en) * 2004-04-23 2007-11-01 エグザジェン ダイアグノスティクス インコーポレイテッド Compositions and methods for prognosis of breast cancer
US7593483B2 (en) * 2004-05-07 2009-09-22 Broadcom Corporation Nonlinear mapping in digital-to-analog and analog-to-digital converters
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
AU2005249446A1 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of IMPDH pathway
EP2471921A1 (en) * 2004-05-28 2012-07-04 Asuragen, Inc. Methods and compositions involving microRNA
EP1756309A2 (en) * 2004-06-03 2007-02-28 Bayer HealthCare AG Methods for predicting and monitoring response to cancer therapy
US8019801B1 (en) * 2004-06-23 2011-09-13 Mayo Foundation For Medical Education And Research Techniques to rate the validity of multiple methods to process multi-dimensional data
WO2006015312A2 (en) * 2004-07-30 2006-02-09 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
JP2008512441A (en) * 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク Method for treating cognitive impairment using pyridyloxymethyl and benzisoxazole azabicyclo derivatives
FR2875512B1 (en) * 2004-09-17 2011-02-04 Diagnogene S A DIAGNOSTIC BIOPUCE OF METASTATIC OR LOCALIZED CHARACTER OF A MAMMARY TUMOR, METHOD AND KIT OF USE
AU2005289756B2 (en) * 2004-09-22 2011-10-13 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
US20060211008A1 (en) * 2004-09-22 2006-09-21 Perry Mongroo Beta-parvin expression for use in diagnostic methods for assessment of breast cancer
GB0421838D0 (en) * 2004-09-30 2004-11-03 Congenia S R L Cancer markers
EP1797429A2 (en) * 2004-09-30 2007-06-20 Bayer HealthCare AG Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
US8747867B2 (en) 2004-09-30 2014-06-10 Ifom Fondazione Instituto Firc Di Oncologia Molecolare Cancer markers
US8065093B2 (en) * 2004-10-06 2011-11-22 Agency For Science, Technology, And Research Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
EP1815021A2 (en) * 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
EP2302054B1 (en) 2004-11-12 2014-07-16 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006061430A2 (en) * 2004-12-10 2006-06-15 Proskelia Bone metastasis markers as a target regulating bone metastasis and bone development
EP1851543A2 (en) * 2005-02-24 2007-11-07 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
DE102005013846A1 (en) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
US20060223075A1 (en) * 2005-03-29 2006-10-05 Exagen Diagnostics, Inc. Unique sequence hybridization probes (USP)
US7919246B2 (en) * 2005-04-07 2011-04-05 Novartis Vaccines And Diagnostics, Inc. SEMA4D in cancer diagnosis, detection and treatment
WO2006119494A2 (en) * 2005-05-04 2006-11-09 Exagen Diagnostics, Inc. Acute myelogenous leukemia biomarkers
US8046777B2 (en) * 2005-06-02 2011-10-25 The Mathworks, Inc. Calling of late bound functions from an external program environment
EP1920056A1 (en) * 2005-07-25 2008-05-14 Oncotherapy Science, Inc. Compositions and methods for treating breast cancer
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
CN101443357A (en) 2005-08-12 2009-05-27 先灵公司 MCP1 fusions
WO2007030611A2 (en) * 2005-09-09 2007-03-15 The Board Of Regents Of The University Of Texas System A calculated index of genomic expression of estrogen receptor (er) and er related genes
US7582441B1 (en) 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease
EP1954820A1 (en) * 2005-10-25 2008-08-13 Het Nederlands Kanker Instituut Prediction of local recurrence of breast cancer
FR2892730A1 (en) * 2005-10-28 2007-05-04 Biomerieux Sa Detecting the presence/risk of cancer development in a mammal, comprises detecting the presence/absence or (relative) quantity e.g. of nucleic acids and/or polypeptides coded by the nucleic acids, which indicates the presence/risk
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2006308870B2 (en) 2005-10-31 2012-08-16 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8014957B2 (en) * 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US7875274B2 (en) * 2005-12-16 2011-01-25 The Board Of Trustees Of The Leland Stanford Junior University Protein modulators of resistance to alkylating agents
EP2363205A3 (en) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
WO2007120753A2 (en) * 2006-04-11 2007-10-25 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of bladder cancer
WO2008013589A2 (en) * 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
DK2021792T3 (en) * 2006-05-09 2013-05-21 Univ British Columbia Dissolved protein arthritis markers
EP2530168B1 (en) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Microfluidic Devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
DE602007013405D1 (en) * 2006-07-14 2011-05-05 Us Government METHOD FOR DETERMINING THE PROGNOSIS OF ADENOCARCINOMA
US7502767B1 (en) * 2006-07-21 2009-03-10 Hewlett-Packard Development Company, L.P. Computing a count of cases in a class
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
CA2663962A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2008037700A2 (en) * 2006-09-27 2008-04-03 Siemens Healthcare Diagnostics Gmbh Methods for breast cancer prognosis
WO2008049953A1 (en) 2006-10-23 2008-05-02 Neocodex, S.L. In vitro method for prognosis and/or diagnosis of hypersensitivity to ooestrogens or to substances with ooestrogenic activity
WO2008061672A2 (en) * 2006-11-24 2008-05-29 Synthon B.V. Genetic risk factor for cancer
EP2104735A2 (en) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-21 regulated genes and pathways as targets for therapeutic intervention
EP2104737B1 (en) * 2006-12-08 2013-04-10 Asuragen, INC. Functions and targets of let-7 micro rnas
WO2008073919A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
CN101622350A (en) * 2006-12-08 2010-01-06 奥斯瑞根公司 miR-126 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008123867A1 (en) * 2007-04-05 2008-10-16 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of breast cancer
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
EP2167138A2 (en) * 2007-06-08 2010-03-31 Asuragen, INC. Mir-34 regulated genes and pathways as targets for therapeutic intervention
SI2171090T1 (en) * 2007-06-08 2013-07-31 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090186015A1 (en) * 2007-10-18 2009-07-23 Latham Gary J Micrornas differentially expressed in lung diseases and uses thereof
CN101925364B (en) 2007-11-27 2014-04-30 不列颠哥伦比亚大学 14-3-3 antagonists for prevention and treatment of arthritis
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
FR2924946B1 (en) * 2007-12-18 2010-02-26 Oreal COSMETIC USE OF ACID CERAMIDASE-LIKE PROTEINS
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
US8105777B1 (en) 2008-02-13 2012-01-31 Nederlands Kanker Instituut Methods for diagnosis and/or prognosis of colon cancer
US20110130296A1 (en) * 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
US7833721B2 (en) * 2008-03-14 2010-11-16 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
US20090253780A1 (en) * 2008-03-26 2009-10-08 Fumitaka Takeshita COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
BRPI0908290A2 (en) * 2008-05-09 2015-07-21 Koninkl Philips Electronics Nv "guideline-based clinical decision support system (cdss)"
US8093000B2 (en) 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
EP2133433A1 (en) * 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
ES2338843B1 (en) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas GENOMIC FOOTPRINT OF CANCER OF MAMA.
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2010047310A1 (en) * 2008-10-20 2010-04-29 大日本住友製薬株式会社 Tumor antigen peptide and use thereof
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
ES2343996B1 (en) * 2008-12-11 2011-06-20 Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz METHOD FOR SUBCLASSIFICATION OF TUMORS.
EP2391962B1 (en) * 2009-01-28 2016-12-21 University of Notre Dame du Lac Accelerated progression relapse test
WO2010093872A2 (en) 2009-02-13 2010-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular-based method of cancer diagnosis and prognosis
DK2406633T3 (en) 2009-03-11 2019-04-01 Augurex Life Sciences Corp COMPOSITIONS AND PROCEDURES FOR CHARACTERIZING ARTHRITIC CONDITIONS
EP3415235A1 (en) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation of microfluidic droplets
WO2010127338A1 (en) * 2009-05-01 2010-11-04 Nuvera Biosciences, Inc. Index of genomic expression of estrogen receptor (er) and er-related genes
EP2486149B1 (en) * 2009-08-06 2015-06-17 John Wayne Cancer Institute Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
US9555089B2 (en) 2009-08-18 2017-01-31 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
EP2483813A1 (en) 2009-10-01 2012-08-08 Chipdx LLC System and method for classification of patients
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP3556867A1 (en) * 2009-11-23 2019-10-23 Genomic Health, Inc. Methods to predict clinical outcome of cancer
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
EP2534267B1 (en) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
NZ602700A (en) 2010-04-01 2014-10-31 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
EP2576816B1 (en) * 2010-05-28 2017-09-27 Biomérieux Method and kit for discriminating between breast cancer and benign breast disease
RU2016149485A (en) 2010-07-12 2018-10-31 Селджин Корпорейшн SOLID FORMS OF ROMIDEPSIN AND THEIR APPLICATION
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
KR102504750B1 (en) 2010-09-29 2023-03-02 어젠시스 인코포레이티드 Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
JP5899236B2 (en) * 2010-12-16 2016-04-06 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． System and method for medical decision support for treatment planning using case-based reasoning
KR101287600B1 (en) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 Prognostic Genes for Early Breast Cancer and Prognostic Model for Early Breast Cancer Patients
EP2670849A1 (en) 2011-02-03 2013-12-11 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
EP2694963B1 (en) 2011-04-01 2017-08-02 Qiagen Gene expression signature for wnt/b-catenin signaling pathway and use thereof
EP3709018A1 (en) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Microfluidic apparatus for identifying components of a chemical reaction
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
CN104011068A (en) 2011-10-21 2014-08-27 奥古雷克斯生命科学公司 Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
US20130130310A1 (en) * 2011-10-24 2013-05-23 Atossa Genetics, Inc. Absorbent paper and use thereof for breast cancer detection
JP5939705B2 (en) * 2012-02-08 2016-06-22 カシオ計算機株式会社 Subject determination device, subject determination method, and program
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
US20130218593A1 (en) * 2012-02-19 2013-08-22 International Business Machines Corporation Usage of assigned treatment in clinical decision support systems
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
CA2875710C (en) 2012-06-22 2021-06-29 John Wayne Cancer Institute Molecular malignancy in melanocytic lesions
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
JP2015536933A (en) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods of treating neuroendocrine tumors using Wnt pathway binding agents
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
JP2016510411A (en) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with WNT pathway inhibitors
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9477906B2 (en) 2013-09-16 2016-10-25 Biodesix, Inc. Classification generation method using combination of mini-classifiers with regularization and uses thereof
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
GB201502840D0 (en) * 2015-02-20 2015-04-08 Univ Cardiff Cancer prognostic
RU2017140779A (en) * 2015-04-24 2019-05-24 Дзе Дженерал Хоспитал Корпорейшн COMPOSITIONS FOR CANCER TREATMENT
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
US10861604B2 (en) 2016-05-05 2020-12-08 Advinow, Inc. Systems and methods for automated medical diagnostics
US20180330059A1 (en) * 2017-05-09 2018-11-15 James Stewart Bates Patient treatment systems and methods
US11164679B2 (en) 2017-06-20 2021-11-02 Advinow, Inc. Systems and methods for intelligent patient interface exam station
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US11348688B2 (en) 2018-03-06 2022-05-31 Advinow, Inc. Systems and methods for audio medical instrument patient measurements
US10939806B2 (en) 2018-03-06 2021-03-09 Advinow, Inc. Systems and methods for optical medical instrument patient measurements
US20210198753A1 (en) * 2018-06-21 2021-07-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for determining a treatment course of action
CN112379093B (en) * 2020-10-22 2023-06-16 上海良润生物医药科技有限公司 Application of CST-Cathepsin complex as tumor diagnosis marker
CN116773815B (en) * 2023-08-14 2023-11-10 四川省医学科学院·四川省人民医院 Application of SLC2A6 as treatment target and screening target and breast cancer screening kit

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US6342491B1 (en) 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
WO1995019369A1 (en) 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5677125A (en) 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE69637552D1 (en) 1995-03-17 2008-07-10 Wayne John Cancer Inst Detection of breast metastases using a multi-marker test
CA2239951A1 (en) 1995-12-08 1997-06-12 The Government Of The United States, Represented By The Secretary, Depar Tment Of Health And Human Services Method and compositions for monitoring dna binding molecules in living cells
CA2279361A1 (en) 1997-01-31 1998-08-06 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin e
US6028189A (en) 1997-03-20 2000-02-22 University Of Washington Solvent for oligonucleotide synthesis and methods of use
US6432707B1 (en) 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6107034A (en) 1998-03-09 2000-08-22 The Board Of Trustees Of The Leland Stanford Junior University GATA-3 expression in human breast carcinoma
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
CA2379212A1 (en) 1999-07-16 2001-01-25 Rosetta Inpharmatics, Inc. Methods for determining the specificity and sensitivity of oligonucleotides for hybridization
US7013221B1 (en) 1999-07-16 2006-03-14 Rosetta Inpharmatics Llc Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
AU2596901A (en) 1999-12-21 2001-07-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001051628A2 (en) 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002008262A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-5 proteins and related reagents and methods of use thereof
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
WO2002085298A2 (en) 2001-04-20 2002-10-31 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
AU2002316251A1 (en) 2001-06-18 2003-01-02 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
TW200512927A (en) 2003-08-08 2005-04-01 Koninkl Philips Electronics Nv Method for determining optimal resist thickness
CA2558808A1 (en) 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LI ET AL: "Role of transforming Growth Factor beta in Lymphatic Metastasis in Breast Cancer", INT. J. CANCER, vol. 79, 1998, pages 455 - 459, XP002985833 *
LUPARELLO ET AL: "Tissue Inhibitor Metalloprotease (TIMP)-1 and Proliferative behaviour of Clonal Breast Cacner Cell", BREAST CANCER RESEARCH AND TREATMENT, vol. 54, 1999, pages 235 - 244, XP002985834 *
SINGHAL ET AL: "Elevated Deoxycytidine and Thymidine Kinase Activities in Human Breast Carcinoma Cells: Inhibition by Difluorodeoxycytidine and Azidodeoxythymidine", PROCEEDINGS OF THE INTERNATIONAL CANCER CONGRESS, vol. 2, October 1994 (1994-10-01), NEW DELHI, pages 1377 - 1381, XP008045762 *
VAN HUL ET AL: "Identification of Third EXT-like Gene (EXTL3) Belonging to the EXT Gene Family", GENOMICS, vol. 47, 1998, pages 230 - 237, XP002931579 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment

Also Published As

Publication number Publication date
US7171311B2 (en) 2007-01-30
WO2004065545A2 (en) 2004-08-05
JP2006519591A (en) 2006-08-31
JP4619350B2 (en) 2011-01-26
EP1590433A2 (en) 2005-11-02
US20040058340A1 (en) 2004-03-25
CA2513642A1 (en) 2004-08-05
EP1590433A4 (en) 2008-10-01

Similar Documents

Publication Publication Date Title
WO2004065545A3 (en) Diagnosis and prognosis of breast cancer patients
WO2002103320A3 (en) Diagnosis and prognosis of breast cancer patients
WO2006015312A3 (en) Prognosis of breast cancer patients
Massagué Sorting out breast-cancer gene signatures
Schlomm et al. Clinical significance of p53 alterations in surgically treated prostate cancers
Kagara et al. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer
Li et al. BRAF mutation in papillary thyroid carcinoma
Misawa et al. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer
Casadio et al. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach
Sushma et al. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population
JP2024001068A (en) Dna methylation markers for noninvasive detection of cancer and uses thereof
Eyvazi et al. CpG islands methylation analysis of CDH11, EphA5, and HS3ST2 genes in gastric adenocarcinoma patients
Demidenko et al. Decreased expression of MT1E is a potential biomarker of prostate cancer progression
Rubin et al. Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer
Oczko-Wojciechowska et al. Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
Pang et al. Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features
Lai et al. Decreased expression of the long non-coding RNA MLLT4 antisense RNA 1 is a potential biomarker and an indicator of a poor prognosis for gastric cancer
Zolotov Genetic testing in differentiated thyroid carcinoma: Indications and clinical implications
Guzzetta et al. The promise of methylation on beads for cancer detection and treatment
Dong et al. Increased EXT1 gene copy number correlates with increased mRNA level predicts short disease-free survival in hepatocellular carcinoma without vascular invasion
Jiang et al. Transcription factor 21 (TCF21) rs12190287 polymorphism is associated with osteosarcoma risk and outcomes in East Chinese population
Yan et al. Association of β-catenin, APC, Smad3/4, TP53, and cyclin D1 genes in colorectal cancer: a systematic review and meta-analysis
Liao et al. Relationship between LINC00341 expression and cancer prognosis
Alsofyani et al. Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma
Noruzinia et al. Young breast cancer: novel gene methylation in WBC

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006500977

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2513642

Country of ref document: CA

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004702566

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004702566

Country of ref document: EP